u/Civil-Community-1367

CELH dropped 10% after a strong earnings report, trading below $30; revenue growth for the flagship brand is 6–8%. The market is treating CELH as a low-growth staple, but the earnings strength and low price may indicate a value opportunity if growth stabilizes or re-accelerates. Long CELH as a contrarian value play on a brand that still has strong earnings but is temporarily discounted due to slowing top-line growth. Further deceleration in revenue growth, increased competition in the energy drink space, or macroeconomic headwinds reducing consumer spending.

Novo launched a superior dose of Wegovy (HD) with better efficacy, at a competitive price point, and expanded access via telehealth partnerships. This strengthens Novo's competitive moat against Eli Lilly and could drive market share growth and revenue upside, potentially not yet reflected in the stock price ahead of critical May 5th earnings. Positive product cycle news and strategic moves create a near-term catalyst for the stock, supporting the author's view of potential undervaluation. Earnings miss on May 5th; stronger-than-expected competitive response from Eli Lilly (LLY); regulatory pushback on pricing or distribution.